MDM2 / MDMX inhibitory peptide, composition, preparation method and application
Through the combination of MDM2/MDMX inhibitory peptides with human serum albumin and vetepofen complexes, a self-assembled composition is formed, targeting the ubiquitination degradation pathway, and activating the p53 pathway, which solves the problem of photodynamic therapy in retinal blasts. The problem of poor results in tumor treatment significantly enhances the sensitivity and therapeutic effect of cancer cells to ROS.
Patent Information
- Application Number
- CN202411035707.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-31
AI Technical Summary
Photodynamic therapy is poor in the treatment of retinoblastoma, mainly due to targeting problems, and the tumor suppressor p53 is often suppressed in these cancers and is difficult to reactivate.
Develop a MDM2/MDMX inhibitory peptide with human serum albumin and vetepofen complex, which binds through hydrophobic bonds and hydrogen bonds, and is modified by Au ion coordination and thiol to form a self-assembled composition, targeting Ubiquitination degradation pathway increases the expression of p53 protein and ROS, and enhances the sensitivity of cancer cells to photodynamic therapy.
This composition can effectively degrade MDM2/MDMX protein, activate the wild-type p53 pathway, enhance the sensitivity of cancer cells to ROS, significantly inhibit cancer cell growth, and significantly reduce tumor volume in animal models, and improve the effect of photodynamic therapy.
Smart Images

Figure CN118955647A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology and relates to an MDM2 / MDMX inhibitory peptide, a composition, a preparation method and an application thereof. Background Art
[0002] Retinoblastoma (RB) is a common intraocular malignancy occurring in infants and children. Conventional chemotherapy and radiotherapy may induce the formation of secondary tumors. Photodynamic therapy (PDT) has shown great promise as a non-invasive and selective therapy. PDT has obvious advantages in treating small tumors in transparent media such as the vitreous body. However, due to many problems such as targeting, PDT is not effective in treating RB.
[0003] The tumor suppressor p53 plays a vital role in many physiological processes. In most human cancers, it is mutated or functionally inactivated, and RB is no exception. In a considerable proportion of cancers, wild-type TP53 (encoding p53 protein) is present, but the protein's action is inhibited, so reactivating p53 is a potential strategy for treating cancer. MDM2 (also known as HDM2) and MDMX (also known as HDMX or MDM4) are two major negative regulators of p53. MDM2 inhibits p53-mediated transcriptional activation by binding to the N-terminal activation domain of p53, and acts as a ubiquitin E3 ligase to ubiquitinate p53 through the ubiquitin-proteasome pathway and hydrolyze it under the action of the proteasome. MDMX mainly binds to the transcriptional activation domain of p53, inhibiting the transcriptional activity of p53 on its downstream genes, but does not mediate the degradation of p53. Therefore, inhibiting MDM2 and MDMX can reactivate p53, so MDM2 / MDMX inhibitors have become the focus of the development of tumor therapeutic drugs. Summary of the invention
[0004] The present invention aims to at least solve the technical problem that PDT has poor performance when used for RB treatment. To this end, the present invention proposes MDM2 / MDMX inhibitory peptides, compositions, preparation methods and applications.
[0005] In one aspect, the present invention relates to an MDM2 / MDMX inhibitory peptide, the amino acid sequence of which is shown in SEQ ID NO: 1, wherein SEQ ID NO: 1 is RRRCKFERQANPAKGFQHYWNCLRRSVR.
[0006] In another aspect, the present invention relates to a complex in which human serum albumin and verteporfin are bound by hydrophobic bonds and hydrogen bonds.
[0007] Furthermore, in the composite provided by the present invention, the ratio of human serum albumin to verteporfin is 10 to 2.5: 1 by mass ratio. Preferably, the ratio of human serum albumin to verteporfin is 5:1.
[0008] On the other hand, the present invention provides a composition, characterized in that it is obtained by self-assembly of the modified MDM2 / MDMX inhibitory peptide and the complex;
[0009] The structure of the composition is:
[0010]
[0011] Wherein, MMDP is the MDM2 / MDMX inhibitory peptide according to claim 1, HSA is the complex according to any one of claims 2 to 3, S is a sulfur atom, Au + For gold ions.
[0012] Furthermore, in the composition provided by the present invention, the ratio of the MMDP to the HSA is 0.5 to 2:1 by mass ratio.
[0013] In another aspect, the present invention relates to use of the complex or the composition in preparing a drug for treating cancer.
[0014] Furthermore, in the application provided by the present invention, the cancer is retinoblastoma.
[0015] Furthermore, in the application provided by the present invention, the cancer therapeutic drug cooperates with photodynamic therapy to treat cancer.
[0016] On the other hand, the present invention relates to the use of the MDM2 / MDMX inhibitory peptide in the preparation of cancer therapeutic drugs.
[0017] Furthermore, in the application provided by the present invention, the MDM2 / MDMX inhibitory peptide targets the MDM2 / MDMX protein in the ubiquitination degradation pathway, increases the expression of p53 protein and ROS, and inhibits the growth of cancer cells.
[0018] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages:
[0019] PDT can utilize photosensitizers to generate cytotoxic reactive oxygen species (ROS) through light exposure. The present invention provides a complex in which human serum albumin and verteporfin are bound by hydrophobic bonds and hydrogen bonds, and the complex itself can generate reactive oxygen species through photodynamic action. In addition, the present invention also provides an MDM2 / MDMX inhibitory peptide, which can selectively bind to the grooves on the surfaces of MDM2 / MDMX and Von Hippel Lindau factor (VHL), target ubiquitination and degradation of MDM2 / MDMX protein, increase the expression of p53 protein and ROS, and inhibit the growth of cancer cells. The present invention encapsulates the complex in Au by Au ion coordination and thiol modification of the MDM2 / MDMX inhibitory peptide. + -The surface of the thiol-peptide complex is self-assembled to obtain a composition. The composition is based on the characteristics of MDM2 / MDMX inhibitory peptide targeting ubiquitination degradation pathway and degrading MDM2 / MDMX protein, which in turn enhances the activation of wild-type p53 pathway, sensitizes PDT, and aggravates mitochondrial damage, and achieves the effect of sensitization and synergistic photodynamic therapy for cancer by regulating RB cells to increase their sensitivity to ROS. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the technical solution of the present invention, the drawings involved in the description of the embodiments will be briefly introduced below. Obviously, the drawings in the description are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0021] Figure 1 Schematic diagram of the design and construction of ANP. (A) is the molecular structure of heme; (B) is the schematic diagram of the construction of ANP; (C) is the schematic diagram of the biological function of ANP.
[0022] Figure 2 Characterization of the physical and chemical properties of ANP. (A) is the molecular docking analysis of verteporfin and paclitaxel with human serum albumin (HSA); (B) is the detection of VP using a steady-state transient fluorescence spectrometer after adding verteporfin. HSA Fluorescence intensity changes; (C) HPLC detection of VP loading efficiency at different ratios; (D) MMDP Au Infrared spectra of MMDP and ANP (wavelength scanning range: 800-4000nm); (E) Au (F, G) are the morphology, size and EDS spectra of ANPs; (H) MMDP Au and zeta potential of ANPs; (I) Colloidal stability test of ANPs at pH 7.4 and 6.0 for 24 h.
[0023] Figure 3 ANP combined with PDT inhibits the growth of Y79 / WERI-Rb1 cells in vitro by increasing the expression of p53 protein and ROS, leading to mitochondrial damage. (A) shows the p53 activation peptide-loaded nanoparticles (VPs) loaded with 10 μM p53 at different ratios on WERI-Rb1 and Y79 cells. HSA 、V L B. V M B. V H B) After 4 h of treatment, cells were exposed to 0, 1, 2, or 4 J of light. After 48 h, cell viability was assessed using the MTT assay (n=4, mean ± SD); (B) WERI-Rb1 and Y79 cells were treated with 5 μM VP HSA and ANPs, and were stimulated by 0.5 J of light. Proteins were collected 48 hours later, and p53 protein expression was analyzed and quantified by Western blotting; (C, D) WERI-Rb1 and Y79 cells were exposed to 10 μM VP HSA or ANPs, and then subjected to 1 J of light stimulation. Intracellular GSH (reduced glutathione) levels were measured using a GSH assay kit; (E, F) Quantification of cellular ROS levels. WERI-Rb1 and Y79 cells were treated with 10 μM MMDP Au VP HSA and ANP treatment. The cells were then labeled with a ROS probe (DCFH-DA) and exposed to 1J of laser stimulation. A separate intervention group was treated with 50μM H2O2 as a positive control; (G,H) After stimulation, flow cytometry analysis was performed to assess cell fluorescence intensity; (I) Mitochondrial activity was measured. WERI-Rb1 and Y79 cells labeled with JC-1 probe were treated with 10μM MMDP Au VP HSA and ANPs and were subjected to a light dose of 1 J. After 12 h, mitochondrial apoptosis was measured and analyzed using flow cytometry; (J) TEM images of mitochondria induced by PDT injury. WERI-Rb1 and Y79 cells were treated with 10 μM MMDP Au and ANP treatment; the ANP(light) group received additional light stimulation. After 48 h, cells were collected, stained, and imaged using TEM.
[0024] Figure 4 ANP combined with PDT leads to the regression of Y79 tumors in NOD / SCID mice. (A) is a schematic diagram of the establishment of a subcutaneous xenograft model using Y79 cells and the treatment plan and schedule. Mice were randomly divided into four groups (n=3 in each group) and received MMDP Au / VP HSA / ANP combined with PDT intravenous injection treatment; (B) photos of subcutaneous tumors in different groups; (C, D) growth curve and weight of Y79 tumors in NOD / SCID mice, representative (E) H&E staining and (F) TUNEL staining of tumor sections and TUNEL quantification (scale bar: 40μm); immunohistochemical images of ki67 (G), 4-HNE (H), BAX (I), Bcl2 (J), p53 (K), and p21 (L) in Y79 tumors and representative IHC images of their statistical analysis (M) (scale bar: 150μm); data are expressed as mean ± standard deviation; *, p<0.05, **, p<0.01, ***, p<0.001, ****, p<0.0001.
[0025] Figure 5 Figure 1 shows the regression of WERI-Rb1 tumors in Balb / c nude mice induced by ANP combined with PDT. (A) The orthotopic xenograft model of retinoblastoma was established by intraretinal injection of WERI-Rb1 cells. The mice were randomly divided into four groups (n=3 in each group) and received VP HSA / ANP combined with PDT intravenous injection treatment; (B) is a photo of the WERI-Rb1 xenograft model of combined treatment; (C) is a representative H&E staining of WERI-Rb1 tumor sections (scale bars: 500μm and 40μm), (D) is a representative TUNEL staining of WERI-Rb1 tumor sections and its quantification (scale bar: 40μm), immunohistochemical images of ki67 (E), 4-HNE (F), BAX (G), Bcl2 (H), p53 (I), and p21 (J) in WERI-Rb1 tumors and their statistical analysis (scale bars: 500μm and 40μm); (K) is the data obtained by IHC of each protein under different treatments, expressed as mean ± standard deviation; *, p<0.05, **, p<0.01, ***, p<0.001, ****, p<0.0001.
[0026] In the above figure, MDM2 / MDMX inhibitory peptide is referred to as MMDP; the complex obtained by combining verteporfin (VP) and human serum albumin (HSA) through hydrophobic bonds and hydrogen bonds is referred to as VP HSA ; MDM2 / MDMX inhibitory peptide is modified and abbreviated as MMDP Au ,MMDP Au and VP HSA The composite obtained by self-assembly is referred to as ANP; V L B represents ANP with low MMDP ratio, V M B represents ANP with a moderate proportion of MMDP, V H B represents the ANP with a higher proportion of MMDP. DETAILED DESCRIPTION
[0027] The technical scheme of the present invention is described below in conjunction with the embodiments, but the present invention is not limited to the following embodiments. The experimental methods and detection methods described in each embodiment are conventional methods unless otherwise specified; the reagents and materials described are all commercially available unless otherwise specified.
[0028] In the following examples, MDM2 / MDMX inhibitory peptide is referred to as MMDP; the complex obtained by combining verteporfin (VP) and human serum albumin (HSA) through hydrophobic bonds and hydrogen bonds is referred to as VP HSA ; MDM2 / MDMX inhibitory peptide is modified and abbreviated as MMDP Au ,MMDP Au and VP HSA The self-assembled composite is referred to as ANP.
[0029] Example 1
[0030] This embodiment provides MMDP, VP HSA , preparation of ANPs.
[0031] MDM2 / MDMX inhibitory peptides were synthesized on appropriate resins on a CS bio 336X automated peptide synthesizer using an optimized HBTU activation / DIEA in situ neutralization protocol developed from the HBTU / HOBT protocol of Fmoc Chemistry SPPS.
[0032] Human serum albumin was purchased from SAITONG H10014.
[0033] MMDP Au The preparation steps are:
[0034] Based on the full chemical synthesis technology of peptides, chemical solid phase peptide synthesis (SPPS) developed by Kent and his colleagues, the HBTU / HOBt-based Fmoc method optimized HBTU activation / DIEA in situ neutralization scheme provided by ABI, the required PROTAC peptide MMDP was synthesized on the MBHA resin using an automatic peptide synthesizer (CS bio 336X), and finally additional right-handed cysteine and arginine residues were introduced into the C-terminus. Purification was performed using preparative reverse HPLC, and the purification solvent was acetonitrile and water containing one thousandth of trifluoroacetic acid (TFA), and the synthesis yield and purity were measured.
[0035] Under magnetic stirring, MMDP and NH2-PEG n-SH (MW 2000Da) was mixed into HAuCl4 solution at a mass ratio of 1:1; then, HEPES (pH 7.4) was added, and the solution color changed to purple, yielding [Au 1+ -S-pep] polymer precursor MMDP Au .
[0036] Based on the all-chemical solid phase peptide synthesis technology (SPPS), ABI provided an HBTU / HOBt-based Fmoc method optimized HBTU activation / DIEA in situ neutralization scheme, using an automatic peptide synthesizer (CSbio 336X) to synthesize the required PROTAC peptide MMDP on MBHA resin, and finally introduce additional right-handed cysteine and arginine residues to the C-terminus. Purification and freeze-drying were performed using preparative reverse HPLC, and the mobile phase was acetonitrile and water containing one thousandth of trifluoroacetic acid (TFA). Finally, LC-MS was used to detect the synthesis yield and purity of the peptide.
[0037] Under magnetic stirring at 50°C and 500 rpm, the peptide MMDP and NH2-PEG n -SH (MW 2000Da) was mixed into HAuCl4 solution at a mass ratio of 1:1; then, HEPES (pH 7.4) was added, and the solution color changed to milky white, and [Au 1+ -S-pep] n Polymer Precursor MMDP Au .
[0038] VP HSA The preparation steps are:
[0039] Human serum albumin HSA was reduced using an environmentally friendly reducing agent TCEP, mixed with vertiporfin at a mass ratio of 5:1, and stirred thoroughly in a light-proof condition to allow for full combination.
[0040] The preparation steps of ANP are:
[0041] In the HEPES reducing environment, VP HSA With MMDP Au The solution was mixed, 5 nm gold nanoparticles with a concentration of 1 mM were added as crystal nuclei, and heated and stirred until the solution turned from turbid to clear.
[0042] ANP design and construction Figure 1 As shown, ANP can effectively degrade MDM2 / MDMX proteins in the ubiquitination degradation pathway and significantly induce cell death through VP-mediated photodynamic therapy (VP-PDT) caused by mitochondrial damage.
[0043] Heme, a naturally occurring organic compound, has a key property of being able to form stable coordination complexes with metal ions ( Figure 1 A)——Metal ions can coordinate with the heme molecule through nitrogen atoms in the middle. By adopting this method, this example first designed a peptide-derived MDM2 / MDMXPROTAC called MMDP, which was used to selectively bind to the grooves on the surface of MDM2 / MDMX and Von Hippel Lindau factor (VHL), and coordinate with Au ions to form a peptide called MMDP. Au Supramolecular gold(I)-thiol-peptide complex ( Figure 1 B) The subsequent step involves encapsulation of VP-bound human serum albumin (HSA) into the MMDP Au The surface of the supramolecular structure initiates the intermolecular assembly driven by multi-point binding interactions between VP and HSA ( Figure 1 B). The reassembled artificial nanoprotein, named ANP, is expected to effectively degrade MDM2 / MDMX proteins in the ubiquitination degradation pathway and strongly induce VP-PDT-mediated cell death via mitochondrial damage ( Figure 1 C).
[0044] Through molecular docking scoring, the present invention unexpectedly found that the hydrophobic cavity of VP and HSA has good binding ability, such as Figure 2 As shown in A, the molecular docking score of the predicted VP is comparable to that of paclitaxel, and its binding area ratio is significantly higher than that of paclitaxel. The binding conformation revealed that VP binds to HSA mainly through hydrophobic bonds and hydrogen bonds. Figure 2 As shown in B, as the concentration of VP increases, the interaction between VP and the hydrophobic cavity of HSA increases. This interaction adjusts the solution environment of tryptophan, resulting in fluorescence quenching. Figure 2 C The concentration of free VP in solutions with different HSA:VP ratios was measured by high performance liquid chromatography (HPLC); when the mass ratio of HSA:VP was 5:1, VP reached the optimal loading ratio, with a loading ratio of up to 93.9%. Figure 2 The infrared spectrum of D confirmed that MMDP Au The self-assembly of MMDP is mainly triggered by the Au-S bond between the peptide and the gold atom. The infrared spectrum of ANP also shows the characteristic absorption peak of the porphyrin ring, which means that Au and VP HSA The self-assembly combination was completed and ANPs were produced. Figure 2 E and Figure 2 F shows that in VP HSA With the addition of , it forms bridges with multiple gold ions, and the smaller size (about 20nm) of MMDP AuThe triggered self-assembly into ANPs of larger size (about 79.4 nm) has the following structure:
[0045]
[0046] Figure 2 G and Figure 2 This was further verified by energy dispersive X-ray spectroscopy (EDS) analysis and transmission electron microscopy (TEM) elemental overlay images showing the uniform distribution of nitrogen (N), oxygen (O), sulfur (S) and gold (Au) within the ANPs. These results indicate that the ANPs have excellent uniformity and are consistent in composition with the matrix. Considering the negative charge of HSA, it is similar to MMDP. Au In contrast, the zeta potential of ANPs experienced a negative shift, further confirming the successful integration of HSA in the polymer.
[0047] To further verify the pharmaceutical properties of ANP, Figure 2 In I, ANP particles remained monodisperse and showed little size change over 24 h in PBS containing 20% fetal bovine serum, either at pH 7.4 or pH 6.0. To investigate the metabolic behavior of ANP drugs in vivo, an experiment was performed in which mice eyes (OS) were injected with 197 Subsequently, ICP-MS was used to detect and quantify the Au-containing ANPs at different time intervals. 197 The presence of Au. The study found that over time, about 90% of the drug in the eye was eliminated within 24 hours. In addition, the drug showed a fluctuating trend in the liver and spleen, indicating that it was metabolized through these organs. After 3 days, the amount of Au detected in all organs was 197 There were minimal traces of Au, confirming that ANPs do not accumulate in vivo and can be effectively removed. Next, to examine the cellular internalization ability of ANPs, fluorescein isothiocyanate (FITC) was attached to the N-terminus of MMDP to create FITC-MMDP and FITC-ANP, respectively. After incubation of the drug with the cells, flow cytometry showed that the control group had almost no fluorescence signal. In contrast, although the MMDP group showed some fluorescence, the green fluorescence signal displayed by ANPs was almost twice that of the MMDP group, indicating superior cellular internalization ability. Overall, these results confirm that ANPs exhibit several favorable properties, including exceptional stability, efficient removal from organisms, and effective cell membrane permeability.
[0048] Example 2
[0049] This example provides the effect and mechanism of ANP combined with photodynamic therapy on the activity of retinoblastoma cell line.
[0050] To evaluate the effect of different concentrations of MMDP on the anticancer activity in vitro, four ANPs with different concentrations of MMDP (including VP without MMDP) were synthesized at the same VP concentration. HSA , V of low concentration MMDP L B. V of medium concentration MMDP M B (also conventional ANP), V with high concentration of MMDP H B) to further determine the MMDP Au The best load. Among them, VP without MMDP HSA The mass ratio of HSA and VP is 5:1, and the V L The mass ratio of HSA to VP in B is 5:1 and the mass ratio of HSA to MMDP is 1:0.5. The V M The mass ratio of HSA to VP in B is 5:1 and the mass ratio of HSA to MMDP is 1:1. H The mass ratio of HSA to VP in B was 5:1 and the mass ratio of HSA to MMDP was 1:2.
[0051] After photodynamic therapy (PDT) of retinoblastoma cell lines, V L B. V M B and V H B and VP HSA Compared with the Figure 3 A). At 2 J / cm 2 At laser intensity of M Group B achieved an inhibition rate of 50-60% in RB and Y79 cell lines. Figure 3 B verified that ANP promoted the expression of tumor suppressor p53. WB experiments were performed in retinoblastoma cell lines. The expression of p53 in the ANP group was about 20% and 25% higher than that in the control group, respectively. This is the difference between ANP and VP. HSA The reason why MMDP exhibits a stronger anti-cancer effect Au Enhanced VP HSA Anticancer effect under photodynamic therapy ( Figure 3 A). Considering that photodynamic therapy can cause cell damage by increasing the accumulation of reactive oxygen species (ROS), the concentration of the intracellular reduced compound glutathione was evaluated, and the level of intracellular reactive oxygen species (ROS) was assessed using flow cytometry. Figure 3 C and Figure 3 D shows that compared with the control group, VP HSA The amount of reduced glutathione (GSH) in the cells of the VP group and the ANP group decreased significantly. Unexpectedly, the decrease in GSH concentration in the ANP group was greater than that in the VP group. HSAThe WERI-Rb1 group decreased by 3.95 μM, while the Y79 group decreased by 14.57 μM. Flow cytometry data showed that after photodynamic therapy, MMDP Au VP HSA The ROS concentrations in the ANP and WERI-Rb1 groups increased, with the ANP group showing the most significant increase in ROS content (WERI-Rb1 Figure 3 EG and Y79 Figure 3 FH), which is consistent with the trend of decreased GSH content. The above experimental results verify that ANP can increase p53 levels, thereby increasing ROS accumulation and enhancing the sensitivity of photodynamic therapy.
[0052] Excessive accumulation of reactive oxygen species (ROS) in cells is one of the main mechanisms leading to mitochondrial damage, which may ultimately lead to cell death. Mitochondrial membrane potential is a key indicator of mitochondrial health, and any damage to mitochondria may lead to a decrease in this potential. The JC-1 test is an effective method to assess mitochondrial membrane potential. When this potential is reduced, JC-1 mainly exists in monomeric form, and the green fluorescence is more significant; conversely, when the potential is high, the red signal is more significant. Therefore, the ratio of green fluorescence to red fluorescence serves as a quantifiable representation of mitochondrial membrane potential. JC-1 flow cytometry results ( Figure 3 I) showed that compared with the control group, MMDP Au VP HSA ANP and VP can reduce mitochondrial membrane potential. It is worth noting that the increase in membrane potential caused by ANP is most obvious in WERI-Rb1 and Y79 cell lines, which is 2.3 times higher than VP and 1.5 times higher than VP, respectively. HSA The MMDP group was 12.45% and 12.57% higher. Au The membrane potential decreased slightly after treatment, which may be attributed to the chronic mitochondrial damage caused by p53 upregulation. Figure 3 J) Reveal that MMDP Au Treatment of WERI-Rb1 and Y79 cells with ANPs resulted in changes in mitochondrial morphology, including deformation, swelling, and loss of mitochondrial cristae. With subsequent photodynamic therapy, mitochondria underwent further changes, including condensation and increased density. This confirms that the combination of ANPs and photodynamic therapy can significantly alter the mitochondrial membrane, cause damage to mitochondria, and ultimately lead to tumor cell death.
[0053] Example 3
[0054] This example provides that ANP combined with photodynamic therapy inhibits retinoblastoma in a subcutaneous model.
[0055] To evaluate the efficacy of ANP, a subcutaneous tumor model was created by injecting cultured Y79 cells into NOD / SCID mice. The mice were then randomly divided into four groups: PBS or MMDP were injected into the tail vein. Au VP HSA Drugs, ANP drugs combined with photodynamic therapy (PDT) ( Figure 4 A). When the experiment reached the endpoint, the tumors were dissected and photographed. The results showed that all other groups had a significant reduction in tumor size compared to the control group, with the ANP drug-treated group showing the smallest tumor volume ( Figure 4 B) Tumor volume was recorded daily and a growth curve was subsequently plotted. This further demonstrated that MMDP Au VP HSA The combination of ANP and PDT significantly inhibited the growth of subcutaneous tumors in mice. Among them, the combination of ANP and PDT showed the most effective inhibitor, with a tumor growth inhibition rate (TGI) of 89.7% ( Figure 4 C). Afterwards, the tumors were weighed, and the results confirmed that the combination of ANP and PDT treatment had a more significant inhibitory effect on tumor growth ( Figure 4 D). In addition, ANP treatment significantly increased the level of apoptosis compared with the control treatment group ( Figure 4 E and Figure 4 F) Overall, the combined treatment of ANP and PDT is more effective in inhibiting tumor growth than MMDP alone. Au or VP HSA Combination with PDT.
[0056] Considering that the surge in reactive oxygen species (ROS) levels tends to damage biological membranes such as mitochondria by producing lipid oxidation products such as 4-HNE, immunohistochemistry (IHC) analysis was performed on Y79 tumor tissues. In the treated tumors, especially in the ANP group, the expression of 4-HNE was increased, while Ki67 was decreased ( Figure 4 G and Figure 4 H). This means that ANP may significantly increase the level of oxidative stress, thereby promoting apoptosis. In this process, BAX, as an important member of the BCL2 protein family, plays a key role in regulating cell apoptosis. The increase in BAX suggests the onset of cell apoptosis, while the decrease in Bcl2 indicates a decreased ability to inhibit cell death. The changes in BAX and Bcl2 expression by ANP treatment are beneficial to cell apoptosis, which is consistent with the anti-cancer goal ( Figure 4 I and Figure 4J). These findings further confirm the significant pro-apoptotic effect of combining ANP with PDT. In addition, p53 and its downstream element p21 were found to be effective in inhibiting the proliferation of retinoblastoma and promoting apoptosis. Immunohistochemistry (IHC) results also showed that, especially in MMDP Au and ANP groups, compared with the other groups, p53( Figure 4 K) and p21( Figure 4 L) levels increased significantly. It is worth noting that MMDP Au No significant difference was observed between the MMDP group and the ANP group. However, the tumor inhibition rate in the ANP group was higher than that in the MMDP group. Au and VP HSA The group was more than 20% higher ( Figure 4 C). These data may infer that successful activation of p53 can enhance the effect of VT-PDT and inhibit tumor growth. In summary, the clear switch from cell proliferation to apoptosis, especially in the ANP group, provides strong support for the therapeutic potential of combining ANP with photodynamic therapy (PDT). This suggests that such a therapeutic strategy can effectively increase oxidative stress within tumor tissues, leading to their self-destruction.
[0057] Example 4
[0058] This example provides that ANP combined with photodynamic therapy inhibits tumor growth in an orthotopic RB mouse model.
[0059] An orthotopic retinoblastoma model was established by injecting WERI-Rb1 cells into the vitreous cavity of Balb / c nude mice. After the model was established, the mice were randomly divided into three different groups: CON, VP, and HSA group and ANP group. PBS, VP and HSA and intravitreal injection of ANP drugs. Comprehensive modeling and treatment options such as Figure 5 A. Photographs of model eyes (OS) of three different groups of mice with retinoblastoma were taken ( Figure 5 B). It is noteworthy that the retina of the CON group showed a distinct white color; in contrast, this was less obvious in the two experimental groups. In particular, the white area in the ANP group was the smallest, which proved that the treatment was indeed effective. This further proved that the combination of ANP and PDT treatment achieved better results. After the experiment was completed, the model eyes were extracted for H&E staining ( Figure 5 C). It was clearly observed that the tumor area in the CON group was the most extensive, with its invasion extending to the anterior chamber. However, the tumor area in the treatment groups was significantly smaller, with the ANP group having the smallest area. Figure 5D) Further analysis revealed a higher incidence of positively stained cells in the ANP group. This suggests an increased rate of apoptosis in this group, confirming the effectiveness of ANP treatment and supporting earlier observations.
[0060] In order to further clarify the mechanism of combined treatment of tumors by ANP (nanoparticles) and PDT (photodynamic therapy), we performed IHC staining ( Figure 5 E~J) and scored accordingly ( Figure 5 K). Ki67 staining showed that the number of positive cells in the ANP group was significantly lower than that in the CON (control group) and VP HSA The results of 4-HNE (4-hydroxynonenal) staining further demonstrated that its expression level in the ANP group was higher than that in the CON group and VP group. HSA This emphasizes that the combination of verteporfin and photodynamic therapy can significantly enhance the production of 4-HNE. Given that 4-HNE is considered a byproduct of lipid peroxidation and a marker of oxidative stress, increased levels may lead to cytotoxic consequences and may be responsible for the observed inhibition of tumor cell growth. This insight enhances our understanding of the antiproliferative mechanisms involved in ANP treatment. BAX( Figure 5 G) and Bcl2( Figure 5 H) Results, in parallel with the subcutaneous tumor model, confirmed that verteporfin concomitant photodynamic therapy (ANP) indeed exhibited a significant pro-apoptotic effect, reinforcing its role in promoting cell death within the tumor. In addition, immunohistochemical staining for p53 and p21 showed that the ANP group had a significant pro-apoptotic effect compared with CON and VP HSA Group( Figure 5 I and Figure 5 J) have higher expression levels. This means that ANP may enhance p53, a known tumor suppressor, to promote cell cycle arrest and apoptosis. Therefore, increased p53 expression may enhance the effectiveness of PDT in eliminating retinoblastoma cells. These conclusions are consistent with previous findings from cell experiments and Y79 animal prototypes, further supporting the potential applicability of ANP treatment in fighting tumors.
[0061] The above results demonstrate the effectiveness of ANP in targeted degradation of MDM2 / MDMX proteins, which in turn enhances activation of the wild-type p53 pathway, sensitizes PDT, and exacerbates mitochondrial damage, ultimately leading to cell death. Moreover, the therapeutic efficacy of ANP in both subcutaneous and orthotopic RB mouse models further strengthens its potential as a promising candidate for clinical translation of RB treatment. Importantly, ANP exhibited a very favorable biosafety profile, a prerequisite for any therapeutic intervention. In short, ANP presents itself as a highly efficient photosensitizer and a potential candidate for clinical translation of RB treatment by reactivating the p53 pathway. This study reveals a new perspective in the field of RB treatment, optimizing therapeutic approaches not only for survival but also for improving ocular function and quality of life.
[0062] The above-described embodiments are part of the embodiments of the present invention, but not all of them. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but rather represents selected embodiments of the present invention. All other embodiments obtained without creative work and related deductions and substitutions made by ordinary technicians in the field under the conditions of the concept of the present invention belong to the scope of protection of the present invention.
Claims
1. A MDM2 / MDMX inhibitory peptide, It is characterized in that The amino acid sequence of the MDM2 / MDMX inhibitory peptide is shown in SEQ ID NO: 1, and SEQ ID NO: 1 is RRRCKFERQANPAKGFQHYWNCLRRSVR.
2. A composite, It is characterized in that Human serum albumin and verteporfin are bound by hydrophobic bonds and hydrogen bonds.
3. The complex according to claim 2, It is characterized in that In terms of mass ratio, the ratio of human serum albumin to verteporfin is 10-2.5:
1.
4. A composition, It is characterized in that Obtained by self-assembly of the modified MDM2 / MDMX inhibitory peptide according to claim 1 and the complex according to any one of claims 2 to 3; The structure of the composition is: Wherein, MMDP is the MDM2 / MDMX inhibitory peptide according to claim 1, HSA is the complex according to any one of claims 2 to 3, S is a sulfur atom, Au + For gold ions.
5. The composition according to claim 4, It is characterized in that In terms of mass ratio, the ratio of the MMDP to the HSA is 0.5 to 2:
1.
6. Use of the complex according to any one of claims 2 to 3 or the composition according to any one of claims 4 to 5 in the preparation of a cancer therapeutic drug.
7. The use according to claim 6, It is characterized in that The cancer is retinoblastoma.
8. The use according to claim 7, It is characterized in that The cancer therapeutic drug synergistically sensitizes photodynamic therapy for cancer.
9. Use of the MDM2 / MDMX inhibitory peptide according to claim 1 in the preparation of cancer therapeutic drugs.
10. The use according to claim 9, It is characterized in that The MDM2 / MDMX inhibitory peptide targets ubiquitination to degrade MDM2 / MDMX protein, increases the expression of p53 protein and ROS, and inhibits the growth of cancer cells.
Citation Information
Patent Citations
Polypeptide nanocomposite as well as preparation method and application thereof
CN112807326A
Human serum albumin linkers and conjugates thereof
US20110059076A1
High affinity and dual-specificity peptide antagonists of MDM2 and MDMX for p53 activation
WO2021091871A1
